In one-year up­date, Alzheon goes big talk, but shows off lit­tle clin­i­cal da­ta

As Bio­gen pulls its glob­al Aduhelm ap­pli­ca­tions left and right, Alzheon — an­oth­er small­er Mass­a­chu­setts-based biotech — claims (again) it has “in­dus­try-lead­ing” da­ta on its …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER